Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Cancer Res. 2019 Jan 18;79(6):1239–1251. doi: 10.1158/0008-5472.CAN-18-2725

Fig. 3. Loss of laminin-411 expression in glioblastoma cells significantly decreases in vivo tumor burden and prolongs survival of tumor-bearing mice.

Fig. 3.

A. Magnetic resonance imaging (MRI) was performed to assess the brain tumor volume in nude mice carrying U87MG cells four weeks after intracranial tumor inoculation. Spin-echo MRI images of the entire brain were acquired from three mice/group, and representative images from mice carrying WT (n=3) vs. laminin-411-DKO (n=3) U87MG gliomas (marked by arrows) are shown. B. Quantification of intracranial tumor volumes derived from WT vs. laminin-411 DKO U87MG cells. (*p = 0.035 by two-tailed Student’s t-test; n = 3). C & D. Survival curves of mice bearing human glioblastoma U87MG (C) and LN229 cells (D). Kaplan-Meier analyses showed mice with the laminin-411 α4 and β1 DKO tumors exhibited a significantly longer survival than mice carrying the WT glioblastoma cells in both U87MG (median survival WT 67 days (n=8) vs. DKO 93 days (n=10); *p = 0.02 by log rank test) and LN229 cohorts (median survival WT 38 days (n=8) vs. DKO 70 days (n=10); *p = 0.015 by log rank test).